Startseite Clinical management of childhood hyperthyroidism with and without Down syndrome: a longitudinal study at a single center
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Clinical management of childhood hyperthyroidism with and without Down syndrome: a longitudinal study at a single center

  • Tiago Jeronimo Dos Santos ORCID logo , Gabriel Ángel Martos-Moreno , María Teresa Muñoz-Calvo , Jesús Pozo , Fernando Rodríguez-Artalejo und Jesús Argente ORCID logo EMAIL logo
Veröffentlicht/Copyright: 28. Juni 2018

Abstract

Background

The approach to the clinical management of Graves’ disease (GD) is debatable. This study aimed to identify predictors of remission in pediatric GD.

Methods

A longitudinal study of 36 children and adolescents with GD followed from 1997 to 2017 at a single tertiary hospital was performed. Clinical and biochemical parameters, including comorbidities, treatment with anti-thyroid drugs (ATD) or definitive therapy (radioiodine [RIT] and thyroidectomy), and remission as the main outcome were collected. We performed a multivariable logistic regression analysis to identify likely predictors of remission.

Results

Among patients, most were female, in late puberty, with exuberant symptoms at onset. Eleven also suffered from Down syndrome (DS). Thirty-four patients (94%) started on methimazole from disease onset, and 25 (69%) received it as the only therapy, with a mean duration of 2.7±1.8 years. Six changed to RIT and three underwent thyroidectomy; no DS patient received definitive therapy. Remission was higher in DS patients (45% vs. 25%, p=0.24), but afterwards (3.9±2.5 vs. 2.3±1.4 years, p<0.05); there was no significance in relapsing (20% vs. 15%). Females were less likely to reach remission (p<0.05); serum free thyroxine at onset was higher (p<0.05) in patients who required definitive therapy. Thyroid-stimulating immunoglobulin (TSI) values normalized in exclusively ATD therapy, especially from 2 years on (p<0.05).

Conclusions

Males were more likely to achieve remission. TSI values may normalize in GD, notably from the second year of treatment. DS children may benefit with conservative management in GD.


Corresponding author: Prof. Dr. Jesús Argente, Full Professor and Chairman, Department of Pediatrics and Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús. Instituto de Investigación La Princesa, Av. Menéndez Pelayo 65, 28009 Madrid, Spain

Acknowledgments

The authors wish to thank all the personal staff from the Department of Pediatric Endocrinology and from the Department of Preventive Medicine for their assistance to the issues raised during all the steps of the study.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization played no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the report for publication.

References

1. Léger J, Kaguelidou F, Alberti C, Carel JC. Graves’ disease in children. Best Pract Res Clin Endocrinol Metab 2014;28:233–43.10.1159/000363163Suche in Google Scholar PubMed

2. Hanley P, Lord K, Bauer AJ. Thyroid disorders in children and adolescents. JAMA Pediatr 2016;170:1008.10.1001/jamapediatrics.2016.0486Suche in Google Scholar PubMed

3. Srinivasan S, Misra M. Hyperthyroidism in children. Pediatr Rev 2015;36:239–48.10.1542/pir.36.6.239Suche in Google Scholar

4. Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, et al. Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study. Eur J Endocrinol 2011;164:801–9.10.1530/EJE-10-1155Suche in Google Scholar PubMed

5. Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009;2009:132041.10.1186/1687-9856-2009-132041Suche in Google Scholar

6. Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clin Endocrinol (Oxf) 2010;72:358–63.10.1111/j.1365-2265.2009.03717.xSuche in Google Scholar PubMed

7. Hemminki K, Li X, Sundquist J, Sundquist K. The epidemiology of Graves’ disease: evidence of a genetic and an environmental contribution. J Autoimmun 2010;34:J307–13.10.1016/j.jaut.2009.11.019Suche in Google Scholar PubMed

8. Goday-Arno A, Cerda-Esteva M, Flores-Le-Roux JA, Chillaron-Jordan JJ, Corretger JM, et al. Hyperthyroidism in a population with Down syndrome (DS). Clin Endocrinol (Oxf) 2009;71:110–4.10.1111/j.1365-2265.2008.03419.xSuche in Google Scholar PubMed

9. Aversa T, Lombardo F, Corrias A, Salerno M, De Luca F, et al. In young patients with turner or down syndrome, Graves’ disease presentation is often preceded by Hashimoto’s thyroiditis. Thyroid 2014;24:744–7.10.1089/thy.2013.0452Suche in Google Scholar PubMed

10. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011;17:456–520.10.4158/EP.17.3.456Suche in Google Scholar PubMed

11. Rivkees SA. Controversies in the management of Graves’ disease in children. J Endocrinol Invest 2016;39:1247–57.10.1007/s40618-016-0477-xSuche in Google Scholar PubMed

12. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26:1343–421.10.1089/thy.2016.0229Suche in Google Scholar PubMed

13. Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, et al. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. J Pediatr 2014;164:1189–94.10.1016/j.jpeds.2013.12.047Suche in Google Scholar PubMed

14. Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children*. J Clin Endocrinol Metab 1997;82:1719–26.10.1210/jc.82.6.1719Suche in Google Scholar

15. Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics 2008;121:e481–8.10.1542/peds.2007-1535Suche in Google Scholar PubMed

16. Weetman A, DeGroot LJ. Autoimmunity to the thyroid gland. South Dartmouth, MA: Endotext. MDText.com, Inc., 2000.Suche in Google Scholar

17. Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves’ disease treated using antithyroid medication. Thyroid 2007;17:1103–7.10.1089/thy.2007.0072Suche in Google Scholar PubMed

18. De Luca F, Corrias A, Salerno M, Wasniewska M, Gastaldi R, et al. Peculiarities of Graves’ disease in children and adolescents with Down’s syndrome. Eur J Endocrinol 2010;162:591–5.10.1530/EJE-09-0751Suche in Google Scholar PubMed

19. Sobradillo B, Aguirre A, Aresti U, Bilbao A, Fernández-Ramos C, et al. Growth Charts & Tables (translational and longitudinal study) [Curvas y tablas de crecimiento (estudio longitudinal y transversal)]. Available at: https://www.aepap.org/sites/default/files/curvas_orbegozo.pdf.Suche in Google Scholar

20. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170–9.10.1136/adc.51.3.170Suche in Google Scholar PubMed PubMed Central

21. Kaguelidou F, Carel JC, Léger J. Graves’ disease in childhood: advances in management with antithyroid drug therapy. Horm Res Paediatr 2009;71:310–7.10.1159/000223414Suche in Google Scholar PubMed

22. Weetman AP. Graves’ hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab 2006;2:2–3.10.1038/ncpendmet0068Suche in Google Scholar PubMed

23. Abraham P, Avenell A, Watson W, Park C, Bevan J. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev 2010;20:CD003420.10.1002/14651858.CD003420.pub4Suche in Google Scholar PubMed PubMed Central

24. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987;64:1241–5.10.1210/jcem-64-6-1241Suche in Google Scholar PubMed

25. Léger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves’ disease: National Long-Term Cohort Study. J Clin Endocrinol Metab 2012;97:110–9.10.1210/jc.2011-1944Suche in Google Scholar PubMed

26. Jevalikar G, Solis J, Zacharin M. Long-term outcomes of pediatric Graves’ disease. J Pediatr Endocrinol Metab 2014;27:1131–6.10.1515/jpem-2013-0342Suche in Google Scholar PubMed

27. Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, et al. Antithyroid drug treatment for Graves’ Disease in children: a long-term retrospective study at a single institution. Thyroid 2014;24:200–7.10.1089/thy.2012.0612Suche in Google Scholar PubMed

28. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008;93:3817–26.10.1210/jc.2008-0842Suche in Google Scholar PubMed

29. Regueras L, Prieto P, Muñoz-Calvo MT, Pozo J, Arguinzoniz L, et al. Endocrinological abnormalities in 1105 children and adolescents with Down syndrome [Alteraciones endocrinológicas en 1105 niños y adolescentes con síndrome de Down]. Med Clin (Barc) 2011;136:376–81.10.1016/j.medcli.2010.06.029Suche in Google Scholar PubMed

30. Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P. Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest 2015;38:283–94.10.1007/s40618-014-0214-2Suche in Google Scholar PubMed

Received: 2018-03-26
Accepted: 2018-04-23
Published Online: 2018-06-28
Published in Print: 2018-07-26

©2018 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Review
  3. Prevalence of cranial MRI findings in girls with central precocious puberty: a systematic review and meta-analysis
  4. Original Articles
  5. Can having a sibling with type 1 diabetes cause disordered eating behaviors?
  6. Wrist circumference as a novel predictor of obesity in children and adolescents: the CASPIAN-IV study
  7. Evaluation of Mn-superoxide dismutase and catalase gene expression in childhood obesity: its association with insulin resistance
  8. Impact of a group-based treatment program on adipocytokines, oxidative status, inflammatory cytokines and arterial stiffness in obese children and adolescents
  9. Clinical management of childhood hyperthyroidism with and without Down syndrome: a longitudinal study at a single center
  10. Detection of distant metastasis at the time of ablation in children with differentiated thyroid cancer: the value of pre-ablation stimulated thyroglobulin
  11. Random serum free cortisol and total cortisol measurements in pediatric septic shock
  12. Self-assessment of pubertal development in a puberty cohort
  13. Growth, the Mediterranean diet and the buying power of adolescents in Greece
  14. Clinical and molecular genetic characterization of two patients with mutations in the phosphoglucomutase 1 (PGM1) gene
  15. Genetic analysis of three families with X-linked dominant hypophosphatemic rickets
  16. Clinical heterogeneity and molecular profile of triple A syndrome: a study of seven cases
  17. No central adrenal insufficiency found in patients with Prader-Willi syndrome with an overnight metyrapone test
  18. Case Reports
  19. A novel mutation in the proopiomelanocortin (POMC) gene of a Hispanic child: metformin treatment shows a beneficial impact on the body mass index
  20. Hypertriglyceridemia thalassemia syndrome
  21. Severe consumptive hypothyroidism caused by multiple infantile hepatic haemangiomas
Heruntergeladen am 1.12.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem-2018-0132/html
Button zum nach oben scrollen